Researchers emphasized the necessity for larger and longer trials to definitively assess rapamycin's impact on human lifespan and healthspan, as this study was limited by self-reporting and a small sample size.

The study revealed no significant improvements in self-reported physical function, emotional well-being, or social interactions, and symptoms of osteoarthritis remained unaffected.

While most body composition metrics remained unchanged, some blood parameters showed variations based on dosage, particularly among male participants.

A potential side effect noted was an increase in gut dysbiosis markers in males, along with a trend towards increased intestinal permeability in females.

Despite the low efficacy of compounded rapamycin, the observed benefits in women suggest potential longevity advantages, warranting further investigation.

The PEARL trial, a crowdfunded study examining the effects of rapamycin on human aging, was conducted by Dr. Sajid Zalzala and published in the journal Aging.

Lifespan.io successfully raised funds for this trial, capitalizing on rapamycin's growing popularity in longevity research, particularly its association with the mTOR pathway.

The trial involved 114 participants, with an average age of 60, who were administered either 5 mg or 10 mg of rapamycin, or a placebo, over a duration of 48 weeks.

Results indicated that the doses of rapamycin were generally safe, with no significant adverse events reported between the treatment and control groups.

Notably, women in the 10 mg group experienced increased lean tissue mass and reduced pain, while the 5 mg group reported general health benefits across genders.